FDA clears PrecivityAD2 blood test from WashU Medicine startup C2N Diagnostics; detects Alzheimer's amyloid plaques with 90% accuracy using mass spectrometry, replacing invasive spinal taps and brain scans for early diagnosis.

FDA clears blood test to aid evaluation for Alzheimer’s disease | WashU Medicine

Visit the News Hub Biomarker test is based on technology developed at WashU MedicineMatt Miller/WashU MedicineThe FDA has cleared a blood test developed from technology invented at WashU Medicine to aid in diagnosing Alzheimer’s disease. The test, PrecivityAD2, can detect amyloid plaque biomarkers with over 90% accuracy, offering a less invasive alternative to spinal taps and brain scans. The U.S. Food and Drug Administration (FDA) has cleared for marketing an innovative blood test with underlyi...